Publication

Article

BioPharm International

BioPharm International-02-01-2003
Volume16
Issue 2

Outsourcing Outlook: Contract Services' Crystal Ball

Author(s):

by Jim Miller, Bio/Pharmaceutical Outsourcing Report Developments in 2002 such as acquisitions, excess manufacturing capacity, and less funding for biotechnology will continue to affect the industry long into the new year.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
How the 15% US-EU Tariff Cap Affects Bio/pharma
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
© 2025 MJH Life Sciences

All rights reserved.